These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7496126)

  • 1. [Batch documentation of blood products].
    Bornmann L
    Infusionsther Transfusionsmed; 1995 Aug; 22(4):258-63. PubMed ID: 7496126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral safety of human plasma-derived medicinal products: impact of regulation requirements.
    Velthove KJ; Over J; Abbink K; Janssen MP
    Transfus Med Rev; 2013 Jul; 27(3):179-83. PubMed ID: 23886505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic concepts in transfusion medicine. Report on the 1st Graz "Transfusion Medicine" Consensus Conference].
    Lanzer G; Mayr WR
    Anaesthesist; 1995 Mar; 44(3):143-6. PubMed ID: 7762772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Guidelines for electronic-data-processing-controlled serial diagnosis of donor blood samples].
    Fischer-Fröhlich CL; Stoll T; Hanfland P
    Beitr Infusionsther; 1990; 26():420-3. PubMed ID: 1703890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blood donor hemovigilance: impact for donor and recipient safety].
    Hauser L; Beyloune A; Simonet M; Bierling P
    Transfus Clin Biol; 2013 May; 20(2):99-103. PubMed ID: 23587614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Testing of medicinal products produced from pooled plasma].
    Unkelbach U; Hunfeld A; Breitner-Ruddock S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1181-4. PubMed ID: 25213735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen inactivation of labile blood products.
    Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components
    Transfus Med; 2001 Jun; 11(3):149-75. PubMed ID: 11422945
    [No Abstract]   [Full Text] [Related]  

  • 9. [A retrospective study of the practice of "look-back" procedures, on the incidence of HIV-1/2-positive blood donors and the risk of transfusion-associated HIV infection in public-community blood banks in Germany].
    Zeiler T; Kretschmer V; Sibrowski W
    Infusionsther Transfusionsmed; 1994 Dec; 21(6):362-7. PubMed ID: 7873914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Microbial safety of blood products].
    Höher PG
    Infusionsther Transfusionsmed; 1996 Feb; 23(1):42-58. PubMed ID: 8653017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging infectious disease issues in blood safety.
    Chamberland ME; Alter HJ; Busch MP; Nemo G; Ricketts M
    Emerg Infect Dis; 2001; 7(3 Suppl):552-3. PubMed ID: 11485669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modern plasma fractionation.
    Burnouf T
    Transfus Med Rev; 2007 Apr; 21(2):101-17. PubMed ID: 17397761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Costs of safety of blood and blood products].
    Seifried E; Soedel G
    Zentralbl Chir; 1995; 120(8):584-92. PubMed ID: 7571889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.
    Seghatchian J; Hervig T; Putter JS
    Transfus Apher Sci; 2011 Aug; 45(1):75-84. PubMed ID: 21782517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond HIV, HBV and HCV--how to deal with other viruses?
    Minor PD
    Dev Biol (Basel); 2002; 108():15-9. PubMed ID: 12220138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The revision of the European blood directives: A major challenge for transfusion medicine.
    Folléa G; Aranko K;
    Transfus Clin Biol; 2015 Aug; 22(3):141-7. PubMed ID: 26056039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [XMRV is not pathogenic in human and has no significance for the safety of blood and blood products].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2012 Aug; 55(8):1057-60. PubMed ID: 22842897
    [No Abstract]   [Full Text] [Related]  

  • 18. Viral infectivity of albumin and plasma protein fraction.
    Erstad BL
    Pharmacotherapy; 1996; 16(6):996-1001. PubMed ID: 8947970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Techniques of preparation and indications of labile blood products].
    Clément S
    Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Balance module allows consistent monitoring and documentation of the pooling process for nucleic acid amplification technology testing.
    Hourfar MK; Koller M; Roth WK; Kehrli R; Seifried E; Schmidt M
    Vox Sang; 2007 Jul; 93(1):37-41. PubMed ID: 17547563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.